NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

NOVO.B.DK

287.65

+2.13%↑

COLO.B.DK

380.4

+1.09%↑

HLUNB.DK

43.6

-2.64%↓

ZEAL.DK

295.2

+0.82%↑

AMBUB.DK

63.05

+0.08%↑

Home・Aandelen Lijst・Genmab A-S

Genmab A-S

Gesloten

1,621 0.06

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1606

Max

1628

Belangrijke statistieken
By Trading Economics
Inkomsten	21M 52M
Verkoop	-184M 881M
K/W Sectorgemiddelde	18.691 49.052
EPS	8.48
Winstmarge	5.915
Werknemers	3,088
EBITDA	-23M 221M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	-1.49% downside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7.6B 97B
Vorige openingsprijs	1620.94
Vorige sluitingsprijs	1621

Genmab A-S Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jun 2026, 23:56 UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

11 jun 2026, 23:56 UTC

Correlated Moves

ETF Constituents

Macro News

iShares MSCI Brazil ETF trades higher after President Trump's cancellation of military strikes against Iran, boosting global investor confidence.

11 jun 2026, 23:56 UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

11 jun 2026, 23:52 UTC

Michigan Consumer Sentiment Report for June 2026 Forecasts Continued Decline at 46.0 Amid Economic Pressures and Inflation Concerns

11 jun 2026, 23:52 UTC

Investors Await Key U.S. Building Permits Report Amid Cautious Market Sentiment Ahead of June 16 Release

11 jun 2026, 23:52 UTC

Macro Event

News

Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

11 jun 2026, 23:51 UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

11 jun 2026, 23:51 UTC

Correlated Moves

Lam Research Corp is rising in after-market trading, supported by a broader market rally and strong momentum near the upper end of its one-month trading range.

11 jun 2026, 23:51 UTC

Correlated Moves

Costco Wholesale Corp shares are higher in after-market hours, supported by a rising Nasdaq 100 Index and positive sentiment in the consumer staples sector.

11 jun 2026, 23:51 UTC

Trip.com Group Ltd is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain this movement.

11 jun 2026, 23:51 UTC

ETF Constituents

Vanguard FTSE Europe ETF is trading lower in after-market hours, impacted by declines from holdings including HSBC and Diageo, despite a generally higher market.

11 jun 2026, 23:51 UTC

Marriott International Inc. shares declined in after-market hours following Thursday's close, with no specific news identified to explain the movement.

11 jun 2026, 23:51 UTC

PepsiCo Inc shares are higher in after-market hours, driven by a significant overall market trend. The stock remains below its 20-day moving average.

11 jun 2026, 23:51 UTC

Lululemon Athletica is trading lower in after-market hours, reflecting a decline since Thursday's close. It reached a session low earlier in the session.

11 jun 2026, 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

11 jun 2026, 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

11 jun 2026, 23:51 UTC

ETF Constituents

Correlated Moves

Macro News

Global X Copper Miners ETF declines in after-market trading as top holdings BHP and Southern Copper Corporation show slight decreases.

11 jun 2026, 23:51 UTC

Correlated Moves

Microchip Technology Inc is rising in after-market trading, reflecting broader market trends amid the European Central Bank's recent interest rate hike.

11 jun 2026, 23:51 UTC

Social Media

Correlated Moves

Micron Technology is trading higher in after-market hours, supported by positive market trends and favorable social media sentiment ahead of upcoming earnings.

11 jun 2026, 23:51 UTC

Correlated Moves

The Nasdaq 100 Index is higher today, continuing its upward trend. Initial jobless claims rose unexpectedly, but this has not impacted the index's momentum.

11 jun 2026, 23:51 UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

11 jun 2026, 23:46 UTC

Intuitive Surgical Inc. shares are higher in after-market trading, advancing modestly since Thursday's close despite remaining below the 20-day moving average.

11 jun 2026, 23:46 UTC

Oil (Brent) is trading roughly flat with no specific news identified. It remains 7.63% below its 20-day moving average, indicating weak performance.

11 jun 2026, 23:46 UTC

ETF Constituents

Correlated Moves

The Vanguard FTSE Developed Markets ETF is trading higher in after-market hours, buoyed by the European Central Bank's interest rate hike and strong performances from SAP and BP.

11 jun 2026, 23:42 UTC

Housing Starts Data Release on June 16, 2026 Expected at 1.44 Million Amid Mixed Economic Sentiment and Inflation Concerns

11 jun 2026, 23:42 UTC

U.S. Import Prices Expected to Rise Amid Inflation Concerns and Geopolitical Tensions Ahead of June 16 Release

11 jun 2026, 23:42 UTC

U.S. Export Prices Expected to Rise 1% MoM Amid Mixed Economic Sentiment and Geopolitical Tensions Ahead of June 16 Release

11 jun 2026, 23:42 UTC

Market Awaits May Housing Starts Data Amid Economic Uncertainties and Rising Costs.

11 jun 2026, 23:42 UTC

U.S. Building Permits Expected to Rise Slightly to 1.41 Million Amid Cautious Optimism Ahead of June Release

11 jun 2026, 23:42 UTC

Macro News

ETF Constituents

Investor sentiment towards the Consumer Staples Select Sector SPDR Fund improves in after-market trading, buoyed by macro developments and strong performances from key holdings.

Peer Vergelijking

Prijswijziging

Genmab A-S Prognose

Koersdoel

By TipRanks

-1.49% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 2,493.35 DKK -1.49%

Hoogste 3,320 DKK

Laagste 308.417 DKK

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Genmab A-S - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Genmab A-S - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.